Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory submission expected early next year. The FDA approved ranibizumab (Susvimo ...
Northstrive Biosciences has submitted a pre-Investigational New Drug, or pre-IND, meeting request to the FDA for EL-22, a novel myostatin asset ...